Skip to main content
Toggle navigation
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
T
Tait, Jessica
Monash University
PI-103
-
UTILISING PHYSIOLOGICAL LYMPH FLOWS TO ENHANCE A MINIMAL PHYSIOLOGICALLY BASED PHARMACOKINETIC AND QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL FOR BIODISTRIBUTION OF MRNA ENCAPSULATED IN LIPID NANOPARTICLES WITH LIPID 5 IN RATS
Jessica Tait
Favorite
Tammara, Brinda
Johnson and Johnson
PII-078
-
PHARMACOKINETIC BRIDGING OF JNJ-77242113 ORAL SOLUTION AND TABLET FORMULATIONS.
Brinda Tammara
Favorite
Tang, Alice
Genentech, Inc
PII-011
-
CHARACTERIZING QTC PROLONGATION RISK FROM CONCOMITANT MEDICATIONS IN PATIENTS WITH BREAST CANCER AMONG PHARMETRICS PLUS.
Alice Tang
Favorite
Tan, Shawn Pei Feng
The University of Manchester
PT-016
-
DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT
Shawn Pei Feng Tan
Favorite
PWII-002
-
DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT
Shawn Pei Feng Tan
Favorite
Tantawy, Marwa
University of Florida
PI-043
-
ATORVASTATIN AS A CARDIOPROTECTIVE AGENT AGAINST CARFILZOMIB-INDUCED CARDIOTOXICITY IN HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES.
Marwa Tantawy
Favorite
PI-047
-
GENOME-WIDE ASSOCIATION STUDY IDENTIFIES GENETIC VARIANTS ASSOCIATED WITH CARDIOVASCULAR ADVERSE EVENTS IN BREAST CANCER PATIENTS TREATED WITH AROMATASE INHIBITORS: RESULTS FROM THE ALL OF US.
Marwa Tantawy
Favorite
Tan, Zhengqi
Pumas-AI, inc.
PI-032
-
MODEL INFORMED DOSE OPTIMIZATION OF BOTENSILIMAB ALONE AND IN COMBINATION WITH BALSTILIMAB IN PATIENTS WITH SOLID TUMORS
Zhengqi Tan
Favorite
Taskar, Kunal
GSK
E-005
-
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO SUPPORT PEDIATRIC CLINICAL DEVELOPMENT: AN IQ WORKING GROUP PERSPECTIVE ON THE CURRENT STATUS AND CHALLENGES
Kunal Taskar
Favorite
Taylor, Zachary
Cincinnati Children's Hospital Medical Center
PII-064
-
DRUG-DRUG INTERACTION MODEL DESCRIBES HIGH-DOSE METHOTREXATE PHARMACOKINETICS AFTER GLUCARPIDASE RESCUE
Zachary Taylor
Favorite
Thakur, Aarzoo
Department of Pharmaceutical Sciences, Washington State University
PII-007
-
PYRIDOXIC ACID AS ENDOGENOUS BIOMARKER OF RENAL ORGANIC ANION TRANSPORTER ACTIVITY: POPULATION VARIABILITY AND MECHANISTIC MODELING TO PREDICT DRUG-DRUG INTERACTIONS
Aarzoo Thakur
Favorite
PT-001
-
UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.
Aarzoo Thakur
Favorite
PWII-001
-
UTILITY OF A PANEL OF ENDOGENOUS BIOMARKERS TO PREDICT DRUG-DRUG INTERACTIONS AND INTERINDIVIDUAL VARIABILITY INVOLVING ORGANIC ANION TRANSPORTERS 1 AND 3 ACTIVITY.
Aarzoo Thakur
Favorite
Thomas, Cameron
University of Florida
OAI-003
-
REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.
Cameron Thomas
Favorite
PT-008
-
REAL-WORLD CLINICAL OUTCOMES BY P2Y12 INHIBITOR THERAPY AND GENOTYPE IN BLACK VERSUS NON-BLACK PATIENTS FOLLOWING PCI.
Cameron Thomas
Favorite
Thompson, Corbin
Amgen, Inc.
PI-035
-
PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED NEUROENDROCRINE PROSTATE CANCER (NEPC)
Corbin Thompson
Favorite
Tumberger, John
Children's Mercy Kansas City
PT-017
-
FLUOXETINE RESPONSE ASSOCIATED WITH ENANTIOMER ABUNDANCE IN ADOLESCENTS.
John Tumberger
Favorite